Recent findings from peer-reviewed publications and clinical registries, explained in plain language. Each finding includes its evidence stage and a link to the original source.
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Lung CancerPublished: May 18, 2026
New BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → Identified in Lung Cancer
Researchers analyzed 1,896 genes in lung cancer patients and found that high levels of SERPINA3 were associated with poorer outcomes. They also found that SERPINA3 was linked to a type of immune dysfunction in the tumor. This suggests that SERPINA3 may be a useful biomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → for identifying patients at higher risk of lung cancer progression.
Why it matters: This finding could help doctors identify patients who may benefit from more aggressive treatment or closer monitoring.
Efficacy
Tumors with high SERPINA3 expression had shorter overall and progression-free survival (OS: log-rank p=0.016; PFS: log-rank p=0.018).
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Ovarian CancerPublished: May 18, 2026
RUNX2's Role in Ovarian Cancer Resistance
Researchers studied how a protein called RUNX2 affects ovarian cancer cells' sensitivity to chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and their tendency to undergo a type of cell death called ferroptosis. They found that RUNX2 can make cancer cells more resistant to chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and less likely to undergo ferroptosis. The study suggests that RUNX2's activity is linked to another protein called YAP1.
Why it matters: This finding could help scientists understand how ovarian cancer develops resistance to chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and how to develop new treatments.
The study was conducted in lab experiments and may not directly apply to human patients.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Lung CancerPublished: May 18, 2026
New Insights into Lung Cancer Treatment without Tobacco History
Researchers analyzed data from 741 patients with lung cancer who never smoked and didn't have specific genetic mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →. They found that high levels of certain proteins and immune cells in the tumor were associated with better treatment outcomes. The study suggests that combining different treatments may improve results for these patients.
Why it matters: This finding could help doctors choose the best treatment options for patients with lung cancer who don't smoke and don't have specific genetic mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →.
Efficacy
Objective response rate was 23.2%, median progression-free survival was 4.5 months, and median overall survival was 16.8 months.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Lung CancerPublished: May 18, 2026
New Study Links Cancer Treatment to Respiratory Complications
Researchers looked at how a type of cancer treatment called neoadjuvant immunochemotherapy affects patients after thoracic surgery. They found that patients who received this treatment were more likely to experience respiratory problems after surgery. The study suggests that patients who received this treatment had a higher risk of respiratory complications.
Why it matters: This finding could help doctors better understand the risks associated with this treatment and monitor patients more closely after surgery.
This study was a retrospective analysis of 327 patients and may not be representative of all patients who receive this treatment.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Meta-AnalysisStatistical pooling of results from multiple studies.Colorectal CancerPublished: May 18, 2026
Survivorship Programs Help Colorectal Cancer Survivors
Researchers looked at 22 studies involving 2949 colorectal cancer survivors to see if survivorship programs improve their quality of life. They found that these programs may help survivors with physical and mental health. However, the quality of the evidence is not very strong.
Why it matters: This finding could help healthcare providers support colorectal cancer survivors after treatment.
Efficacy
The meta-analysis results showed a significant improvement in physical (SMD = 0.52) and mental domains of HRQoL (SMD = 0.4).
Observational StudyPatterns observed in populations over time, not a controlled experiment.Prostate CancerPublished: May 18, 2026
New Model Helps Predict Prostate Cancer Recurrence
Researchers analyzed data from 3,010 patients who had prostate cancer surgery to see if the amount of cancer left behind affected the likelihood of cancer coming back. They found that several factors, including the size of the remaining cancer, were linked to a higher risk of recurrence. The study suggests that a new model could help doctors predict which patients are at higher risk.
Why it matters: This finding could help doctors better counsel patients and choose the right treatments after prostate cancer surgery.
Efficacy
The 5-year survival rates without biochemical recurrence were 93%, 81%, and 47% for good-, intermediate-, and poor-risk groups, respectively.
ReviewSummary and analysis of existing published studies.Breast CancerPublished: May 18, 2026
Genomic Science and Breast Cancer in Males
Researchers looked at how genomic science can help identify and treat breast cancer in males. They found that individuals with a family history of breast cancer may be at higher risk. This is an area where nurses can play a key role in providing care.
Why it matters: This research highlights the importance of genomic science in understanding and treating breast cancer in males, particularly in those with a family history.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Lung CancerPublished: May 18, 2026
Combining Futibatinib and Binimetinib in Advanced Cancer Treatment
Researchers tested a combination of two cancer drugs, futibatinib and binimetinib, in lab experiments and a small clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation →. They found that the combination showed promise in treating certain types of lung cancer, but the trial was stopped due to side effects. The exact effectiveness of this combination is still unclear.
Why it matters: This study contributes to the ongoing search for effective treatments for advanced cancer, particularly for patients with KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →-mutant non-small cell lung cancer.
The trial was stopped early due to side effects, and the sample size was small.
ReviewSummary and analysis of existing published studies.Breast CancerPublished: May 18, 2026
Mapping Research on Preventing a Common Side Effect of Breast Cancer ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →
Researchers analyzed a large collection of studies on a type of medication called long-acting G-CSF, which helps prevent a serious side effect of breast cancer chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → called febrile neutropenia. They found that the research on this topic has grown rapidly and is now focusing on how to implement it in real-world practice. The study aimed to provide a clear overview of the current state of research on this topic.
Why it matters: This study may help identify future research priorities and provide a framework for navigating the complex evidence base on febrile neutropenia prevention.
The study analyzed a large collection of studies, but it did not present any new data or results.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Breast CancerPublished: May 18, 2026
Kenyan Study Tests New Approach to Increase Breast and Cervical Cancer Screenings
Researchers in Kenya are testing a new program called C3Link to see if it can increase the number of women getting breast and cervical cancer screenings. The program includes community and clinic strategies to address barriers to screening. The study will compare the C3Link program to usual care.
Why it matters: This study could provide insights into how to improve cancer screening rates in low-resource settings.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Breast CancerPublished: May 18, 2026
Obesity Linked to Poorer Outcomes in Young Women with Certain Breast Cancer
Researchers studied 5,094 premenopausal women with a specific type of breast cancer in China. They found that women who were obese had poorer outcomes compared to those who were underweight, normal weight, or overweight. The study suggests that obesity may be an independent risk factor for breast cancer recurrence in these women.
Why it matters: This finding may help doctors better understand how to treat young women with this type of breast cancer and how to manage their weight to improve their prognosis.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Lung CancerPublished: May 17, 2026
Optimal Cancer Care Linked to Better Survival Rates
Researchers studied cancer patients in California and Texas to see how quickly they received treatment and how well it matched guidelines. They found that patients who got timely, guideline-concordant care had better survival rates, but this benefit was reduced for those living in the most vulnerable neighborhoods.
Why it matters: This finding highlights the importance of considering social factors in cancer care and treatment outcomes.
Efficacy
Patients who received optimal care had hazard ratios for death of 0.45 (colon cancer), 0.35 (NSCLC), and 0.46 (pancreatic cancer) compared to those who received least optimal care.
